Sign in
Taking people in United StatesPhase 2

Tests exercise therapy in men with early prostate cancer on active surveillance

Tests whether exercise therapy changes markers of progression in men with localized prostate cancer.

Key facts

Who runs it
City of Hope Medical Center
Where
Basking Ridge, Commack, Duarte, Harrison, Hartford, Los Angeles, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 10 sites
Trial code
Registry title
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Status
Recruiting
Phase
Phase 2
People taking part
102 people, planned
Started
13 Jul 2026
Expected to end
3 Aug 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Exercise Therapy
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with localized prostate cancer who are on active surveillance and do not exercise enough. They will do exercise therapy or have usual care.

Age
18 years or older
Sex
Men only
Disease stage
Localized prostate cancer confirmed by tissue examination, on active surveillance
Earlier treatment
No treatment given before surgery for prostate cancer in the last 5 years. No cancer drug treatment of the whole body in the last 15 years.

Main reasons for not taking part

  • Already exercising 150 minutes a week or more at moderate or vigorous level
  • Cancer that has spread to distant parts of the body
  • Taking part in another program that may change the effect of exercise, such as a weight loss program
  • BMI of 40 kg/m^2 or more
  • Not cleared for exercise by the screening checks

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18
  • Men with histologically confirmed localized prostate cancer undergoing active surveillance
  • Inactive, defined as not meeting the national exercise guidelines for cancer patients (<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch)
  • Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG)
  • BMI <40 kg/m\^2
  • Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B)

Who cannot take part

  • Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years
  • Any history of systemic anticancer therapy in the last 15 years
  • Distant metastatic malignancy of any kind
  • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
  • Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program)

Where in United States

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • City of Hope Medical CenterDuarte, United StatesContact: Lee JonesTaking people
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • Hartford Healthcare ALLIANCE (Data collection only)Hartford, United StatesContact: Andrew Salner, MDNot yet recruiting
  • University of California, Los Angeles (Data and Specimen Analysis Only)Los Angeles, United StatesContact: Paul Boutros, PhDNot yet recruiting
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesContact: Jessica Scott, PhDNot yet recruiting
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)Rockville Centre, United StatesContact: Jessica Scott, PhDNot yet recruiting

About the trial

What the trial wants to find out

To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.

The 2 groups in the trial

  • Participants Assigned to Exercise TherapyTreatment being tested

    Participants with histologically confirmed localized prostate cancer undergoing active surveillance

    Treatment: Exercise Therapy

  • Participants Assigned to Usual CareNo study treatment, for comparison

    Participants with histologically confirmed localized prostate cancer undergoing active surveillance

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer
Plain-language title
Tests exercise therapy in men with early prostate cancer on active surveillanceGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 October 2026